GSK-340 is a BET inhibitor with high affinity and significant selectivity for BD2 from BRD4 with a pIC50 of 7.2. GSK-340 inhibits MCP-1 release in Lipopolysaccharide ( HY-D1056 ) treated PBMCs and whole blood with the pIC50 of 7.4 and 6.0, respectively. GSK-340 has immunomodulatory activity.
Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Epigenetic Reader Domain
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.